Lantana, FL, May 28, 2025 (GLOBE NEWSWIRE) -- JFB Construction Holdings (Nasdaq: JFB), a Real Estate Development and construction company focused on Hospitality, commerical, industrial and residential property development, announces that it has executed new contracts totaling more than $69.5 million to date in 2025. These contracts represent several key business verticals, including hospitality, commercial retail, industrial, high-end residential and real estate development. “This achievement is such an imp ...

一个典型的社交APP会包含前端（移动APP或Web端）、后端（服务器、数据库）以及一些支持工具和服务。北京木奇移动技术有限公司，专业的软件外 包开发公司，欢迎交流合作。 前端是用户直接交互的界面，主要分为移动端（iOS/Android）和Web端。 后端负责处理业务逻辑、数据存储、用户认证、API接口等。 原生开发 (Native Development)： iOS： 语言： Swift (推荐，现代、安全、高性能), Objective-C (老项目维护)。 框架： UIKit (传统UI框架), SwiftUI (新一代声明式UI框架)。 特点： 性 能最佳，用户体验最流畅，可访问设备所有原生功能，但开发成本高（需要分别为iOS和Android开发）。 适用场景： 对性能、动画、用户体验有极 致要求，或需要深度集成Apple生态系统特性的复杂社交APP。 Android： 语言： Kotlin (推荐，现代、简洁、Google官方支持), Java (老项目维护)。 框架： Android SDK (传统UI组件), Jetpack Compose (新一代声 明式UI框架)。 特点： 同iOS原生开发， ...

Core Insights - Belpointe PREP, LLC has announced that its mixed-use development project, VIV, in St. Petersburg, Florida, is approximately 85% complete and is expected to begin leasing later this year [1][3] Group 1: Project Overview - VIV is strategically located in downtown St. Petersburg and aims to become a landmark destination with residential units, modern amenities, and vibrant retail spaces [2][5] - The project is designed to meet the growing demand for high-quality living options in St. Petersburg, providing a unique opportunity for residents and businesses [2][5] Group 2: Company Commitment - The CEO of Belpointe OZ expressed excitement about the project's progress and emphasized the company's commitment to delivering exceptional developments in high-growth markets [3] - The project is part of Belpointe OZ's strategy to create long-term value for investors [3] Group 3: Company Profile - Belpointe OZ is a publicly traded qualified opportunity fund listed on NYSE American under the symbol "OZ" and has over 2,500 units in its development pipeline across four cities, with a total project cost exceeding $1.3 billion [6] - The company has filed registration statements with the SEC for the offer and sale of up to $1.5 billion of Class A units [7]

Core Insights - Belpointe PREP, LLC has announced that its mixed-use development project, VIV, in St. Petersburg, Florida, is approximately 85% complete and is expected to begin leasing later this year [1][3] Group 1: Project Overview - VIV is strategically located in downtown St. Petersburg and aims to become a landmark destination with residential units, modern amenities, and vibrant retail spaces [2][5] - The project is designed to meet the growing demand for high-quality living options in St. Petersburg, providing a unique opportunity for residents and businesses [2][5] Group 2: Company Commitment - The CEO of Belpointe OZ expressed excitement about the project's progress and emphasized the company's commitment to delivering exceptional developments in high-growth markets [3] - The project is part of Belpointe OZ's strategy to create long-term value for investors [3] Group 3: Company Profile - Belpointe OZ is a publicly traded qualified opportunity fund listed on NYSE American under the symbol "OZ" and has over 2,500 units in its development pipeline across four cities, with a total project cost exceeding $1.3 billion [6] - The company has filed registration statements with the SEC for the offer and sale of up to $1.5 billion of Class A units [7]

For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alexander's (ALX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Finance sector should help us answer this question.Alexander's is one of 857 individual stocks in the Finance sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of ...

27日，高新区一宗低密住宅拍卖。地块位于高新区火炬路以南、华中路以东、青岛中学以北，为城镇住宅用地，土地面积62644㎡，最终，该地块 被青岛东方伊甸园文化旅游开发有限公司（金茂控股）竞得，成交楼面价3850元/㎡，成交总价约3.86亿元。 文体设施：现状周边5处文化用地；规划有1处文化用地。 商业设施：现状周边智力岛商业区和金茂商业区；规划周边有海月湖商业区。 城市公园绿地：现状周边伊甸园、祥茂河公园、青岛中学公园；葫芦巷水系公园。 地块周边公服配套的规划和建设情况： 道路交通（地铁）：规划周边有地铁10号线。 教育与医疗：现状周边有3处幼儿园，1处小学，1处九年一贯制学校，一处12年制学校；规划周边有1处九年一贯制学校。 具体来看，地块位于火炬路南、华中路东、祥茂河以西、青岛中学北侧，占地面积约62644㎡，为城镇住宅用地，容积率1.6，建筑面积约10.02万 ㎡，建筑密度≤20%，绿地率≥30%，楼面起拍地价3850元/㎡，起拍总价3.86亿元，保证金1.16亿元。 从地块位置来看，地块位于高新区中心，片区内配套完善，包含商业金茂览秀城、学校青岛中学，以及完成竣工验收即将启用的娱乐配套——东 方伊甸园项 ...

Core Insights - Yoshiharu Global Co. is entering the U.S. real estate market to diversify its growth engines beyond its traditional ramen business [1][4] - The company has signed a strategic MOU with Good Mood Studio and plans to invest approximately $2 million for a 10% stake in Wealthrail, a real estate tokenization platform [2][3] - The U.S. real estate market is viewed as the largest and most attractive globally, with plans to position Yoshiharu as a leading PropTech player [4] Company Overview - Yoshiharu specializes in authentic Japanese ramen and has expanded to operate 15 restaurants across Southern California and Las Vegas since its debut in 2016 [5]

- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. “Initiating dosing in the 10,000-participant portion of this study is a significant st ...

Core Insights - Evaxion A/S is progressing well with its strategy, achieving key milestones and focusing on the execution of its clinical trials and collaborations [2][4][11] - The company is advancing its AI-Immunology™ platform and pipeline, with a focus on personalized cancer vaccines and infectious disease candidates [3][10][31] Business Highlights - The company has achieved the first two milestones for 2025, including the ongoing phase 2 trial of EVX-01 for advanced melanoma, which is expected to yield two-year data in the second half of 2025 [2][4] - Collaboration with MSD on EVX-B2 and EVX-B3 is on track for potential option exercise, which could lead to significant milestone payments and royalties for Evaxion [11][12] Research & Development Update - The phase 2 trial of EVX-01 has shown promising results, with 80% of vaccine targets triggering a tumor-specific immune response, an increase from previous hit rates of 71% and 79% [5][7] - The company is also developing a precision vaccine targeting non-conventional endogenous retrovirus (ERV) tumor antigens, with plans to select a lead candidate in 2025 [7][9] Financial Overview - As of March 31, 2025, cash and cash equivalents were $17.8 million, a significant increase from $6.0 million at the end of 2024, providing a cash runway until mid-2026 [17][27] - The company reported a net loss of $1.6 million for the first quarter of 2025, compared to a net income of $1.2 million for the same period in 2024, primarily due to changes in financial income [22][30] Equity and Liabilities - Total equity improved to $10.3 million as of March 31, 2025, compared to a negative equity of $(1.7) million at the end of 2024, reflecting the company's strengthened financial position [23][27] - The company is in the process of converting €3.5 million of its €7 million loan from the European Investment Bank into an equity-type instrument, expected to enhance financial flexibility [15][16]

Core Insights - Lifecore Biomedical has appointed Mark DaFonseca as chief commercial officer, bringing nearly 30 years of pharmaceutical industry experience, particularly in contract development and manufacturing organizations (CDMOs) [1][2] - DaFonseca will focus on executing a three-pronged growth strategy aimed at enhancing Lifecore's brand, expanding customer partnerships, and growing the business portfolio through new collaborations [1][3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [7] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global biopharmaceutical and biotechnology companies [7] Leadership Experience - Prior to joining Lifecore, DaFonseca held significant roles at CordenPharma, AmbioPharma, and CoreRx, where he led sales, marketing, and project management efforts [2] - His track record includes consistently exceeding key performance indicators in various sales leadership positions within the CDMO sector [2] Strategic Goals - DaFonseca expressed eagerness to leverage Lifecore's assets to strategically grow the business by expanding current customer relationships and increasing the overall customer base [4] - The company aims to enhance its market presence and address the industry's capacity needs through investments in state-of-the-art facilities and equipment [4] Compensation Details - As part of his appointment, Lifecore will grant DaFonseca a restricted stock unit (RSU) award for 20,000 shares and an option for 30,000 shares of common stock [4][5] - The RSU will vest on the third anniversary of the grant date, while the stock option will have a vesting schedule based on continued employment [6]